Navigation Links
Sleep helps people learn complicated tasks
Date:11/17/2008

hooter games, with the goal of killing enemy bots (software avatars that play against the participant) while avoiding being killed.

The subjects were given a pre-test to determine their initial performance level on the games. Then they were trained to play the games and later tested on their performance. One group was trained in the morning and then tested 12 hours later after being awake for that time. A second group was trained in the morning and then tested the next day, 24 hours after being trained. Another group was trained in the evening, then tested 12 hours after a night's sleep and a fourth group was trained in the evening and then also tested 24 hours after training.

When trained in the morning subjects showed an 8 percentage point improvement in accuracy immediately after training. However after 12 waking hours following training, subjects lost half of that improvement when tested in the evening. When subjects were tested the next morning 24 hours after training, they showed a 10 percentage point improvement over their pre-test performance.

"The students probably tested more poorly in the afternoon because following training, some of their waking experiences interfered with training. Those distractions went away when they slept and the brain was able to do its work," Nusbaum said.

Among the students who received evening training, scores improved by about 7 percentage points, and went to 10 percentage points the next morning and remained at that level throughout the day.

The study follows Fenn, Nusbaum and Margoliash's earlier work, published in Nature, which showed for the first time that sleep consolidates perceptual learning of synthetic speech.

"In that study we showed that if after learning, by the end of the day, people 'forgot' some of what was learned, a night's sleep restored this memory loss," Nusbaum said. "Furthermore a night's sleep protected memory against loss over the course of
'/>"/>

Contact: William Harms
w-harms@uchicago.edu
773-702-8356
University of Chicago
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Time to Set Kids Back-to-School Sleep Clocks
2. AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic
3. Sleepless Kids Are Troubled Kids
4. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
5. Work time is the largest influence to the duration of a persons sleep
6. Passive smoking increases sleep disturbance among pregnant women
7. Minorities more likely to have sleep durations associated with increased mortality
8. Lack of sleep among new school-goers leads to behavioral, cognitive problems
9. Work Time Predicts Sleep Time
10. Nicotine in breast milk disrupts infants sleep patterns
11. Pain patients at risk for sleep apnea

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)..., ORLANDO, Fla., Dec. 4 , ,What:...a,s largest Medicare, health benefit... ( http://humanagames.com ), a senior-friendly da... Guidance Center on Tues., Dec. 8 a... free and open to the public, will feature...
(Date:12/4/2009)...ION, N.J., Dec. 4 PLUS Diagnostic...lty anatomic pathology services with the launch of...service completes the company,s expansion from a r...pathology company offering diagnostic services acr...terology, urology and now hematology/oncology. ,...
(Date:12/4/2009)...EATTLE, Dec. 4 The National Cancer...ear contract to Fred Hutchinson Cancer Research Ce...ancer Information Service Contact Center. ,, Th...enter - nearly tripling the size of its current CI...y operational, which is scheduled for March 15, 20...
(Date:12/4/2009)... Lexi-Comp,s multi-language patient educa...to establish standards for language access in heal...udson, OH (PRWEB) December 5, 2009 -- Lexi-Comp, I... solutions, and patient education materials for he...of effective communication between the health care...
(Date:12/4/2009)...ren less likely to get herpes zoster virus, study ...) -- Children who are vaccinated against chicken p...gles, new findings suggest. , U.S. researchers ...n southern California who were vaccinated with the...2008. , Over an average of 2.5 years after rece...
Breaking Medicine News(10 mins):Health News:Humana Launches Dancetown on Tues., Dec. 8 in Kissimmee 2Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 2Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 3Health News:Hutchinson Center Wins $55.4 Million Contract to Become Sole Operator of the NCI Cancer Information Service 2Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 2Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 3
...oimmune disease is a condition in which the immune...gressively as it would attack a foreign pathogen. ... autoimmune disease, and is one of the most common...ttack the central nervous system. It has long been...
...lty from the University of Michigan , University... key collaborators in study , , DETROIT, April ...ecently discovered a chemical that plays a major r...rofessor of psychiatry in the School of Medicine a...
...-Week Data Supports Long-term Use of Vectical(TM) ... Patients - , , FORT WORTH, Texas, April 30 Gald...om a newly published clinical trial in this month,...o-moderate chronic plaque psoriasis. Of those pati...
...ches Women of Hope is Beautiful Campaign to Inspir...confidence, control, community, caring -- ask any...ly find meaning in these words. They are also inte...ent. The program, which is celebrating its 20th an...
...st radiosurgery solutions from Elekta discussed ...t the 2009 American Association of Neurological Su...iego Convention Center, Elekta customers and perso...nd oncologists today. , , Local Control of Brain...
...INTON, Mass., April 30 Alseres Pharmaceuticals, I... that on April 24, 2009 it entered into an Amendme...Therapeutic, Inc. (BioAxone), pursuant to which th...amended. The Amendment replaces all of the pre-co...
Other Medicine News:Health News:Gray matter under attack in multiple sclerosis 2Health News:Gray matter under attack in multiple sclerosis 3Health News:Wayne State University and Children's Hospital of Michigan Research Team Discover Chemical That Plays a Major Role in Pediatric Obsessive-Compulsive Disorder 2Health News:Wayne State University and Children's Hospital of Michigan Research Team Discover Chemical That Plays a Major Role in Pediatric Obsessive-Compulsive Disorder 3Health News:Wayne State University and Children's Hospital of Michigan Research Team Discover Chemical That Plays a Major Role in Pediatric Obsessive-Compulsive Disorder 4Health News:Study Results Published in CUTIS Demonstrate Long-Term Safety and Efficacy of Vectical(TM) (calcitriol) Ointment 3 mcg/g in the Management of Mild-to-Moderate Plaque Psoriasis 2Health News:Study Results Published in CUTIS Demonstrate Long-Term Safety and Efficacy of Vectical(TM) (calcitriol) Ointment 3 mcg/g in the Management of Mild-to-Moderate Plaque Psoriasis 3Health News:Study Results Published in CUTIS Demonstrate Long-Term Safety and Efficacy of Vectical(TM) (calcitriol) Ointment 3 mcg/g in the Management of Mild-to-Moderate Plaque Psoriasis 4Health News:Photos: Look Good. . .Feel Better Celebrates 20 Years of Helping Women Cope With Cancer 2Health News:Photos: Look Good. . .Feel Better Celebrates 20 Years of Helping Women Cope With Cancer 3Health News:Photos: Look Good. . .Feel Better Celebrates 20 Years of Helping Women Cope With Cancer 4Health News:Elekta Radiosurgery Solutions are Creating New Possibilities for the Most Challenging Cases of the Head And Body 2Health News:Elekta Radiosurgery Solutions are Creating New Possibilities for the Most Challenging Cases of the Head And Body 3Health News:Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology 2Health News:Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology 3Health News:Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology 4
(Date:12/3/2009)... Ted Karkus, Chairman an... www.quigleyco.com announced today that the Comp...ies to develop prescription pharmaceutical and OTC... interests to focus primarily on the OTC/Personal ...mited to its Cold-EEZE® and Kids-EEZE® b...
(Date:12/3/2009)...rk and SAN DIEGO, California, December 3 /PRNewswi...miR-122, a microRNA Important for,Hepatitis C Vira...titis C,Virus in the Bloodstream in Chimpanzees Ch..., - SPC3649 Demonstrates Efficacy With No Evi...vents in the Treated Animals - Signaling a Potenti...
(Date:12/3/2009)...re-FirstCall/ -- Cardium Therapeutics (NYSE Amex: ...diary, Tissue Repair Company, submitted a 510(k) p...d Drug Administration (FDA) seeking marketing clea...sed on positive data from the Company,s recently c...submission with the FDA covers Excellagen XL(TM) ...
Breaking Medicine Technology:Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 2Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 4Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 5Lure of Bottled Water May Not Be Health Driven 49525 1WellPoint to Hold Conference Call and Webcast to Discuss Second Quarter Results on July 29 2009 49523 1WellPoint to Hold Conference Call and Webcast to Discuss Second Quarter Results on July 29 2009 49523 2Make Nursing Homes More Like Home 3A Medicare 49521 1Make Nursing Homes More Like Home 3A Medicare 49521 2
...ive Insulin-Based Therapies, Market,Growth Will be...om Decision Resource...ne of the,world,s leading research and advisory fi...s that the most significant driver of growth in th...standard of care away from,regular human insulins ...
...09, SEATTLE, Aug. 12 Cell Therapeutics, Inc.,s,(...cine (SM) announced today,that planned enrollment ...rch and Treatment of Cancer (EORTC) randomized pha...ith newly diagnosed advanced or metastatic,soft ti...he primary,endpoint of the trial is progression-fr...
Other Medicine Technology:Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market 2Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 2Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 3Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 4Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 5Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 6
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
Medicine Products: